Dear Editor, we would like to share ideas on the publication “Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape.Citation1” In order to continue lowering the worldwide burden of coronavirus disease 2019 (COVID-19), Das et al. pointed out that heterologous vaccination regimens, which involve the injection of booster vaccines different from the primary immunization series, are practical, efficient, and secure.Citation1 Das et al. noted that mRNA-based vaccinations that are already on the market and those that are being developed will play a significant global role in preventing individuals from contracting COVID-19 brought on by developing VoCs.Citation1 In order to arrive at an accurate interpretation, a number of criteria must be taken into account. One of the potential complicating factors that could have had an impact on the outcomes of the initial dose was an abnormally poor reaction. The absence of clinical symptoms and asymptomatic COVID-19 may be connected.Citation2 A COVID-19 must be ruled out if neither the previous symptoms nor the current clinical indicators are present. It is impossible to totally rule out the possibility of cross-contamination with an undiagnosed SARS-Co-V2 infection. Depending on inherited genetic variability, various people’s immune systems appear to react to COVID-19 vaccines differently.Citation3 Additional clinical research is required to ascertain the validity of the results and clinical findings of the current work. Finally, it is important to remember that the heterologous study is not a standard, even though we may appreciate the value of the heterologous booster technique. If we think about it, choosing the ineffective COVID-19 vaccine was a means to remedy the earlier poor vaccination planning. The role of the heterologous booster must be confirmed in the event that a good COVID-19 vaccine is utilized as the primary immunization.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Additional information
Funding
References
- Das R, Hyer RN, Burton P, Miller JM, Kuter BJ Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape. Hum Vaccin Immunother. 2023 Jan 11:2153532. doi: 10.1080/21645515.2022.2153532. Online ahead of print.
- Joob B, Wiwanitkit V. Letter to the Editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020 Mar;53(2):70. doi:10.3961/jpmph.20.065.
- Čiučiulkaitė I, Möhlendick B, Thümmler L, Fisenkci N, Elsner C, Dittmer U, Siffert W, Lindemann M. GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. Front Genet. 2022 Aug 29;13:932043. doi:10.3389/fgene.2022.932043.